89 related articles for article (PubMed ID: 26897635)
1. Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.
Ocaña A; Pérez-Peña J; Díez-González L; Sánchez-Corrales V; Templeton A; Seruga B; Amir E; Pandiella A
Breast Cancer Res Treat; 2016 Feb; 156(1):1-8. PubMed ID: 26897635
[TBL] [Abstract][Full Text] [Related]
2. Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.
Pérez-Peña J; Alcaraz-Sanabria A; Nieto-Jiménez C; Páez R; Corrales-Sánchez V; Serrano-Oviedo L; Wali VB; Patwardhan GA; Amir E; Győrffy B; Pandiella A; Ocaña A
Oncotarget; 2017 Mar; 8(13):21733-21740. PubMed ID: 28423514
[TBL] [Abstract][Full Text] [Related]
3. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.
Ocaña A; Pérez-Peña J; Alcaraz-Sanabria A; Sánchez-Corrales V; Nieto-Jiménez C; Templeton AJ; Seruga B; Pandiella A; Amir E
Oncotarget; 2016 Apr; 7(16):22865-72. PubMed ID: 26992217
[TBL] [Abstract][Full Text] [Related]
4. Aurora-A gene is frequently amplified in basal-like breast cancer.
Staff S; Isola J; Jumppanen M; Tanner M
Oncol Rep; 2010 Feb; 23(2):307-12. PubMed ID: 20043089
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathologic aspects of basal-like breast cancers.
Fadare O; Tavassoli FA
Nat Clin Pract Oncol; 2008 Mar; 5(3):149-59. PubMed ID: 18212769
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
7. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
[TBL] [Abstract][Full Text] [Related]
8. Deconstructing the molecular portrait of basal-like breast cancer.
Yehiely F; Moyano JV; Evans JR; Nielsen TO; Cryns VL
Trends Mol Med; 2006 Nov; 12(11):537-44. PubMed ID: 17011236
[TBL] [Abstract][Full Text] [Related]
9. The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
Fadare O; Tavassoli FA
Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437
[TBL] [Abstract][Full Text] [Related]
10. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.
Tell RW; Horvath CM
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12787-92. PubMed ID: 25139989
[TBL] [Abstract][Full Text] [Related]
12. Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis.
Wang Z; Katsaros D; Shen Y; Fu Y; Canuto EM; Benedetto C; Lu L; Chu WM; Risch HA; Yu H
PLoS One; 2015; 10(8):e0136246. PubMed ID: 26287798
[TBL] [Abstract][Full Text] [Related]
13. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
Zhang L; Liu Z; Zhu J
Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
[TBL] [Abstract][Full Text] [Related]
14. Analyzing mRNAsi-Related Genes Identifies Novel Prognostic Markers and Potential Drug Combination for Patients with Basal Breast Cancer.
Huang K; Wu Y; Xie Y; Huang L; Liu H
Dis Markers; 2021; 2021():4731349. PubMed ID: 34646403
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.
Martínez-Canales S; Cifuentes F; López De Rodas Gregorio M; Serrano-Oviedo L; Galán-Moya EM; Amir E; Pandiella A; Győrffy B; Ocaña A
PLoS One; 2017; 12(5):e0175128. PubMed ID: 28472085
[TBL] [Abstract][Full Text] [Related]
16. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
[TBL] [Abstract][Full Text] [Related]
17. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
[TBL] [Abstract][Full Text] [Related]
19. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
Finetti P; Cervera N; Charafe-Jauffret E; Chabannon C; Charpin C; Chaffanet M; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Cancer Res; 2008 Feb; 68(3):767-76. PubMed ID: 18245477
[TBL] [Abstract][Full Text] [Related]
20. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
